Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

90.12 -1.16 (-1.27%)
Streaming Delayed Price Updated: 3:23 PM EST, Dec 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
74 75 Next >
News headline image
Bank Of England Reduces 16-Year High Interest Rates In Divided Decision As Inflation Hits 2% ↗
The Bank of England cuts interest rate for first time in over 4 years to 5%, citing inflation below target and emerging economic slack. Pound falls, UK stocks hold steady. 
Via Benzinga
Topics Economy
News headline image
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? ↗
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
News headline image
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations ↗
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
News headline image
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
From AstraZeneca
Via Business Wire
News headline image
UK Agency Says AstraZeneca's Breast Cancer Drug Enhertu Is Expensive, CEO Pascal Soriot Urges Review Of Drug Pricing Assessment ↗
AstraZeneca CEO Pascal Soriot urges the UK government to reassess drug funding after NICE deems Enhertu too costly, highlighting concerns over new methodology affecting advanced cancer treatments and... 
Via Benzinga
News headline image
3 Surprisingly Underrated Stocks to Buy Right Now ↗
These stocks arguably deserve more respect from investors. 
Via The Motley Fool
News headline image
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
AstraZeneca beat earnings-per-share (EPS) estimates and raised guidance, but shares still fell. Investors should watch for developments around the drug Enhertu. 
Via MarketBeat
Topics ETFs
News headline image
7 Explosive Growth Stocks Set to Soar in 2024 ↗
These seven explosive growth stocks across various sectors have the potential to deliver substantial returns for investors in 2024. 
Via InvestorPlace
News headline image
Why AstraZeneca Stock Is Sliding Today ↗
The British drugmaker's Q2 results were good, but seemingly not good enough for many investors. 
Via The Motley Fool
News headline image
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday? ↗
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown. 
Via Benzinga
Topics Economy
News headline image
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript ↗
AZN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook ↗
The company no longer expects its earnings to decline this year. Instead, AstraZeneca called for stable profit. 
Via Investor's Business Daily
News headline image
AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines ↗
AstraZeneca's Q2 sales rose 13% to $12.94 billion, beating expectations. Oncology sales grew 15% to $5.33 billion. Notable drug performances include Tagrisso up 8%, Calquence up 21%, and Farxiga up... 
Via Benzinga
News headline image
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand ↗
Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast. 
Via Benzinga
News headline image
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House ↗
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech... 
Via Benzinga
Topics Government Stocks
News headline image
AstraZeneca’s H1 and Q2 2024 Financial Results
From AstraZeneca
Via Business Wire
News headline image
AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q2 2024 ↗
AZN stock results show that AstraZeneca missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks ↗
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. 
Via InvestorPlace
News headline image
American Airlines, AstraZeneca And 3 Stocks To Watch Heading Into Thursday ↗
 
Via Benzinga
News headline image
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants ↗
Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints. 
Via Benzinga
News headline image
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife ↗
The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market. 
Via Benzinga
News headline image
Biotech Bull Market Is Intact But SMIDs Are Too Volatile ↗
It was another wild week for the market as it had to contend with a lot of news. 
Via Talk Markets
News headline image
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
News headline image
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now? ↗
The big pharma company's top drug is losing ground, but its dividend keeps rising. 
Via The Motley Fool
News headline image
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally ↗
The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season. 
Via Benzinga
News headline image
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
News headline image
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment ↗
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
News headline image
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024 ↗
Undervalued Nasdaq 100 stocks may not be as rare as hen's teeth but not quite so plentiful amid a raging bull market. 
Via InvestorPlace
News headline image
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns ↗
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside. 
Via InvestorPlace
News headline image
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win ↗
New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying after the election. 
Via Benzinga
Topics ETFs
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.